At the same time, SAN has been proved to be a kind of special P-n

At the same time, SAN has been proved to be a kind of special P-nucleating agent. The addition of SAN into iPP helps enhances the crystallinity and the content of P crystal form of injection-molded specimen. The morphology and the distribution of SAN in iPP matrix have great influence on the SAN’s nucleating activity, which will ultimately affect the final crystalline structures of injection-molded specimens. (C) 2008 Wiley Periodicals, Inc. J Appl Polym Sci 111: 786-793, 2009″
“Two new dammarane-type glycosides, phlomisumbroside A (1) and

phlomisumbroside B (2), together with 15 known compounds (3-17) were isolated from the leaves of Phlomis umbrosa Turcz. Their structures were established by the spectroscopic methods including 2D NMR techniques.”
“BACKGROUND Although hyaluronic

acid (HA) fillers are extensively used for the correction of facial wrinkles and folds, there is a limit to patient satisfaction, AZD1152 concentration especially in patients with severe wrinkles. OBJECTIVE To evaluate the potential for synergistic effects with combined treatment using a nonablative infrared (IR) device and HA filler in the treatment of nasolabial GSK461364 fold (NLF) wrinkles. MATERIALS AND METHODS This was a split-face randomized study in which 12 Korean patients were treated with HA filler on both NLFs and with a nonablative IR device on the experimental side of the face. Clinical evaluations from subjects and investigators and photographs were

obtained at baseline, just before and after the procedures, and 1 and 2 months after completion of the procedures. RESULTS There were no significant differences between wrinkle severity and global aesthetic scores for HA gel implantation alone and HA gel with nonablative IR device treatment at any point. CONCLUSION Combining the use of a nonablative IR device with HA filler does not appear to C646 be superior to HA filler alone in the treatment of moderate to severe NLF wrinkles.”
“Study Design. A prospective, nonrandomized multicenter study of lumbar disc nucleus replacement using the DASCOR Disc Arthroplasty Device. An interim analysis of clinical results is presented, obtained from European patients enrolled in 2 studies.

Objective. To determine the safety and efficacy of the DASCOR Device for the treatment of symptomatic single-level degenerative disc disease (DDD).

Summary of Background Data. Patients suffering from DDD have been limited to a choice between nonoperative therapies or invasive surgical treatments such as total disc replacement or spinal fusion. The DASCOR Device was developed to provide an alternative treatment with a less invasive surgical intervention.

Methods. A total of 85 patients from 11 European centers were enrolled in 1 of 2 studies between February 2003 and July 31, 2007. Data were collected before surgery and after surgery at 6 weeks and at 3, 6, 12, and 24 months.

Comments are closed.